This is Vol.75 Newsletter for May 2026.
May 2026 showed that the biopharma, clinical research, and medical device sectors are moving beyond simple growth and into a phase shaped more by execution, regulation, and operational strategy. From the shift toward patient-centered oncology trials and rising pharmaceutical R&D investment, to the expansion of advanced regenerative medicine, evolving MFDS review reforms, and the growing role of AI in clinical operations, the environment is becoming more interconnected and more execution-driven. In this landscape, long-term competitiveness will depend not only on innovation itself, but on how effectively companies connect development strategy, regulatory planning, infrastructure, and real-world implementation.